Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PDD +15.1%, SDRL +5.3%
Other news:
- RNA +35.1% (expands cardiovascular collaboration with Bristol Myers Squibb (BMY) for up to five targets utilizing Avidity's Proprietary AOC platform technology)
- BITF +16% (places order for miners)
- SWTX +11.1% (receives FDA Approval of OGSIVEO)
- EBS +10.1% (receives $75 mln contract option from BARDA to procure doses of CYFENDUS (Anthrax vaccine adsorbed adjuvanted))
- CWEN +7.1% (joining S&P SmallCap 600)
- CG +5.9% (joining S&P MidCap 400)
- IMVT +4.3% (announces initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults)
- WPC +3.9% (joining S&P MidCap 400)
- INTT +3.2% (authorizes $10 mln repurchase program)
- BUSE +2% (to acquire M&M Bank)
- NVAX +2% (announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing by WHO for active immunization to prevent COVID-19 in individuals aged 12 and older)
- AMLI +1.8% (files semi-detailed environmental impact assessment study to start falchani mine permitting process ahead of schedule)
- ICUI +1.4% (joining S&P SmallCap 600)
- AAOI +1.1% (completed its previously announced $70.0 million "at the market" common stock offering)
- ANAB +1% (exclusive license agreement with Centessa Pharmaceuticals)
Analyst comments:
- LASR +4.2% (upgraded to Speculative Buy from Hold at The Benchmark Company)
- CROX +2.4% (upgraded to Strong Buy from Outperform at Raymond James)
- BA +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- AFRM +1% (upgraded to Hold from Underperform at Jefferies)